base metals investing Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
base metals investing Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
base metals investing Mesoblast Acquires Chimeric Antigen Receptor Platform Technology for Precision-Enhanced Cell Products
base metals investing Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
base metals investing High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
